MARC record from Internet Archive

LEADER: 04971cam 2200637 a 4500
001 ocm56641316
003 OCoLC
005 20220707180729.0
008 040513s2005 enka b 001 0 eng
040 $aNLM$beng$cNLM$dUKM$dC#P$dCUX$dBAKER$dNLGGC$dMUQ$dYDXCP$dCGC$dBTCTA$dOCLNG$dBDX$dOCLCF$dWUM$dOCLCQ$dOCLCO$dZ5A$dUKMGB$dOCLCQ$dOCLCO
015 $aGBA467183$2bnb
016 7 $a101245554$2DNLM
016 7 $a012992115$2Uk
020 $a9781842141823$q(hbk.)
020 $a1842141821$q(hbk.)
035 $a(OCoLC)56641316
042 $anlmcopyc
050 4 $aRC382$b.S383 2005
060 00 $a2005 E-333
060 10 $aWL 359$bS416 2005
082 04 $a616.83306$222
084 $a44.90$2bcl
084 $aG1f6$qUkBrU-I$2cmedlit
245 00 $aScientific basis for the treatment of Parkinson's disease /$cedited by Néstor Gálvez-Jiménez.
246 30 $aParkinson's disease
250 $a2nd ed.
260 $aLondon ;$aNew York :$bTaylor & Francis,$c2005.
300 $axvi, 359 pages :$billustrations (some color) ;$c26 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
500 $a"A Parthenon book."
504 $aIncludes bibliographical references and index.
520 $aCompletely updated including coverage of the Parkin gene, this second edition unveils advances in the genetics of Parkinson's Disease (PD). The author reviews the role of alpha synuclein in the genesis of PD and covers tau protein and related diseases, MPTP and drug induced PD, oxidative stress, mitochondrial dysfunction, and apoptosis. He explores pharmacological approaches to the treatment of PD such as the use of COMT inhibitors and dopamine agonist and advances in technology such as devices that provide additional treatment options including deep brain stimulation and transplantation. The book concludes with new chapters covering the differential diagnosis of PD and related disorders.
505 00 $g1.$tThe basal ganglia /$rS. N. Haber --$g2.$tBasal ganglia, motor control and parkinsonism /$rY. H. Sohn and M. Hallett --$g3.$tThe pathology of Parkinson's disease -- recent advances /$rK. A. Jellinger --$g4.$t[alpha]-Synuclein, nigral degeneration and parkinsonism /$rY. Mizuno, H. Mochizuki and N. Hattori --$g5.$tThe thalamus and Parkinson's disease : clinical, pathological and experimental observations /$rJ. M. Henderson --$g6.$tThe pedunculopontine nucleus : anatomy, physiology and function in locomotion /$rP. A. Pahapill, C. Hamani and A. M. Lozano --$g7.$tGenetics of Parkinson's disease /$rM. Toft and M. Farrer --$g8.$tDopamine agonists /$rM. R. Hanson and N. Galvez-Jimenez --$g9.$tCatechol-o-methyl transferase inhibitors in the treatment of Parkinson's disease /$rA. D. Korczyn --$g10.$tAdvances in the surgical treatment of Parkinson's disease : emphasis on pallidotomy and deep brain stimulation /$rN. Galvez-Jimenez --$g11.$tNew treatment modalities in Parkinson's disease /$rP. Tuite, J. Riss and L. H. Brauer --$g12.$tPsychosis in Parkinson's disease /$rD. P. Wint, M. S. Okun and H. H. Fernandez --$g13.$tDystonia and parkinsonism /$rP. Mir, M. J. Edwards and K. P. Bhatia --$g14.$tFunctional imaging in Parkinson's disease /$rA. Dagher --$g15.$tCell transplantation and gene therapy for the treatment of Parkinson's disease /$rT. Subramanian and M. Deogaonkar --$g16.$tTauopathies and frontotemporal dementia /$rZ. Arvanitakis and Z. K. Wszolek --$g17.$tProgressive supranuclear palsy /$rI. Litvan --$g18.$tCortical-basal ganglionic degeneration /$rD. E. Riley and M. L. Moro-de-Casillas --$g19.$tDiagnosis and treatment of multiple system atrophy : an update /$rG. K. Wenning, F. Geser and W. Poewe --$g20.$tSleep disturbances in Parkinson's disease /$rC. L. Comella --$g21.$tDrug-induced parkinsonism /$rK. D. Sethi and J. C. Morgan --$g22.$tEpisodic and continuous gait disturbances in Parkinson's disease /$rN. Giladi, J. M. Hausdorff and Y. Balash --$g23.$tAutonomic disturbances in Parkinson's disease /$rT. Gurevich and A. D. Korczyn.
650 0 $aParkinson's disease$xTreatment.
650 12 $aParkinson Disease$xtherapy
650 6 $aMaladie de Parkinson$xTraitement.
650 7 $aParkinson's disease$xTreatment.$2fast$0(OCoLC)fst01053702
650 17 $aZiekte van Parkinson.$2gtt
650 17 $aBehandelingsmethoden.$2gtt
700 1 $aGálvez-Jiménez, Néstor.
938 $aBaker & Taylor$bBKTY$c199.95$d.00$i1842141821$n0004155463$sactive
938 $aBrodart$bBROD$n04425324$c$199.95
938 $aBaker and Taylor$bBTCP$nBK0004155463
938 $aTaylor & Francis$bTYFR$n1842141821
938 $aYBP Library Services$bYANK$n2122068
029 0 $aNLM$b101245554
029 1 $aAU@$b000026753872
029 1 $aAU@$b000026759431
029 1 $aAU@$b000028269899
029 1 $aNLGGC$b267911416
029 1 $aYDXCP$b2122068
029 1 $aUKMGB$b012992115
994 $aZ0$bIME
948 $hNO HOLDINGS IN IME - 102 OTHER HOLDINGS